https://clinicaltrials.gov/ct2/show/NCT03683719
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Application of Delgocitinib Cream 1, 3, 8, and 20 mg/g for 16 Weeks in Adult Subjects With Mild to Severe Chronic Hand Eczema
Actual Study Start Date : December 7, 2018
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2020